Dopavision has announced positive topline results from a proof-of-concept trial of MyopiaX, a noninvasive photobiomodulation intervention designed to slow myopia progression in children.“The 6-month outcomes represent a significant step in the clinical development of MyopiaX,” Ian Flitcroft, PhD, FRCOphth, coordinating investigator of the MyopiaX-1 trial, said in a company press
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected.
Enrollment complete for study of MyopiaX app in children, adolescents healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.